Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the treatment process of patients who are prone to high risk of developing severe COVID 19. Materials and Methods: Forty consecutive patients who had received CP at our center were included in the study. Demographics, COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported. Results: Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in 75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%) were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite of a continuous 5 L/min support of O2. 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support and managed to recover from COVID-19. Conclusion: According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a favorable safety profile.
Convalescent plasma, COVID-19, viral infections
GEMİCİ, ALİİHSAN; BİLGEN, HÜLYA; ERDOĞAN, CEM; KANSU, ABDULLAH; OLMUŞÇELİK, OKTAY; BEKÖZ, HÜSEYİN SAFFET; ÇAKMAK, RUMEYSA; MERT, ALİ; and SEVİNDİK, ÖMÜR GÖKMEN
"A single center cohort of 40 severe COVID-19 patients who were treated withconvalescent plasma,"
Turkish Journal of Medical Sciences: Vol. 50:
8, Article 4.
Available at: https://journals.tubitak.gov.tr/medical/vol50/iss8/4